Dr. Key David Mcmurrain Jr., M.D. Preventive Medicine - Preventive Medicine/Occupational Environmental Medicine Medicare: Not Enrolled in Medicare Practice Location: 10180 Capps Ferry Road, Palmetto, GA 30268 Phone: 770-463-0890 Fax: 770-463-0058 |
News Archive
Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its EligenĀ® Technology, today announced that Novartis Pharma AG has agreed to extend the maturity date of Emisphere's Convertible Promissory Note (the "Note") to February 26, 2010.
Twitter may be an effective, untapped resource to stimulate interest in cancer clinical trials and boost enrollment, physicians at the Abramson Cancer Center of the University of Pennsylvania suggest in a new research letter in JAMA Oncology. Analyzing thousands of lung cancer tweets on the social media site revealed that a surprisingly large number were about clinical trials, particularly ones on immunotherapy, although none were used for recruitment.
Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.
› Verified 7 days ago